EMEA-003481-PIP01-23 - paediatric investigation plan

lutikizumab

Key facts

• Active Substance:
  lutikizumab
• Therapeutic area:
  Skin and subcutaneous tissue disorders
• Decision number:
  P/0150/2024
• PIP number:
  EMEA-003481-PIP01-23
• Pharmaceutical form(s):
  Solution for injection
• Condition(s) / indication(s):
  Treatment of hidradenitis suppurativa
• Route(s) of administration:
  Subcutaneous use
• Decision type:
  P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
• Decision date:
  06/05/2024

Decision

P/0150/2024: EMA decision of 6 May 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for lutikizumab (EMEA-003481-PIP01-23)

Reference Number: EMA/155839/2024